Singapore markets close in 45 minutes

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
45.02+3.64 (+8.80%)
At close: 04:00PM EDT
44.16 -0.86 (-1.91%)
After hours: 05:20PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close41.38
Open40.97
Bid44.58 x 200
Ask45.31 x 100
Day's range40.36 - 45.52
52-week range3.03 - 50.42
Volume162,732
Avg. volume281,145
Market cap481.115M
Beta (5Y monthly)2.47
PE ratio (TTM)N/A
EPS (TTM)-6.90
Earnings date06 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est71.00
  • GlobeNewswire

    Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

    NORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that the abstract [No. 3151] for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) annual meeting being held from May 31-June 4, 2024 in Chicago has been released. The ASCO abstract is titled: Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjuga

  • GlobeNewswire

    Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

    NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 2024 RBC Capital Markets Global Healthcare Conference to be held May 14-15, 2024 in New York, NY. 2024 RBC Capital Markets Global Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsPresentation

  • GlobeNewswire

    Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

    Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024 $116M of capital raised in Q1 2024 extending cash runway through Q1 2027 Appointed Dr. Dominic Smethurst as Chief Medical Officer NORWOOD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended Mar